SCHEMBL1476620

SCHEMBL1476620

CCOC(=O)/C(=C/N(C)C)C(=O)c1ccc(F)c(OC)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEP1B Q16820 1/20 0.39
PLIN1 O60240 1/20 0.38
POLB P06746 1/20 0.38
PLIN5 Q00G26 1/20 0.38
ABHD5 Q8WTS1 1/20 0.38
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CYP11B1 P15538 6/20 0.36
CYP11B2 P19099 5/20 0.36
S1PR4 O95977 1/20 0.35
S1PR1 P21453 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116506 1.00 KMT2A (0.40) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL1476623 1.00 KMT2A (0.40) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL14015606 0.90 KMT2A (0.40) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL2601631 0.90 KMT2A (0.40) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL4567541 0.90 CES2 (0.47) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL2083176 0.90 CES2 (0.47) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL2083177 0.90 CES2 (0.47) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL6240709 0.88 MEN1 (0.39) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL6240698 0.88 MEN1 (0.39) KMT2AMEN1MAPTLMNANPSR1
SCHEMBL2079689 0.86 MEN1 (0.43) KMT2AMEN1MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915418-B2 Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-29 US disclosed
US-20060135775-A1 Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-06-22 US disclosed
EP-1632482-A1 INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE QUINOLONECARBOXYLIC ACID DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135775-A1 Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives NQO2, COASY, DHPS KMT2A 3581/4885MEN1 2336/4885MAPT 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.